5月30日,先声药业盘中涨幅一度超过8%,截至发稿上涨5.25%,报12.84港元。公司多款创新药研究成果将在2025年ASCO年会上展示,包括两款在研药物及三款已上市药物的18项研究。此外,先声药业的新药SIM0278和SIM0500分别达成重要国际合作协议,目标市场潜力巨大。浙商证券认为,公司创新药业务将推动2025-2027年业绩快速增长。免责声明:本文内容由开放的智能模型自动生成,仅供参考...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.